相似文献
1
The antagonism by BW A868C of PGD2 and BW245C activation of human platelet adenylate cyclase.
Br J Pharmacol. 1989 Feb;96(2):301-6. doi: 10.1111/j.1476-5381.1989.tb11817.x.
2
The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist.
Br J Pharmacol. 1989 Feb;96(2):291-300. doi: 10.1111/j.1476-5381.1989.tb11816.x.
3
Antagonism of PGD2 vasodepressor responses in the rat in vivo by the novel, selective antagonist, BW A868C.
Br J Pharmacol. 1989 Feb;96(2):307-12. doi: 10.1111/j.1476-5381.1989.tb11818.x.
4
Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets.
Br J Pharmacol. 1985 May;85(1):285-90. doi: 10.1111/j.1476-5381.1985.tb08858.x.
5
Interaction of BW A868C, a prostanoid DP-receptor antagonist, with two receptor subtypes in the rabbit isolated saphenous vein.
Prostaglandins. 1996 Aug;52(2):125-39. doi: 10.1016/0090-6980(96)00058-5.
6
Stimulation of prostaglandin D2 receptors on human platelets by analogs of prostacyclin.
Prostaglandins. 1991 Aug;42(2):105-19. doi: 10.1016/0090-6980(91)90070-v.
7
AH6809, a prostaglandin DP-receptor blocking drug on human platelets.
Br J Pharmacol. 1988 Jul;94(3):745-54. doi: 10.1111/j.1476-5381.1988.tb11584.x.
8
The role of prostanoid TP- and DP-receptors in the bronchoconstrictor effect of inhaled PGD2 in anaesthetized guinea-pigs: effect of the DP-antagonist BW A868C.
Br J Pharmacol. 1990 Aug;100(4):761-6. doi: 10.1111/j.1476-5381.1990.tb14089.x.
9
Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Eur J Pharmacol. 1995 May 26;289(3):455-61. doi: 10.1016/0922-4106(95)90154-x.
引用本文的文献
1
Bioactive lipid regulation of platelet function, hemostasis, and thrombosis.
Pharmacol Ther. 2023 Jun;246:108420. doi: 10.1016/j.pharmthera.2023.108420. Epub 2023 Apr 24.
2
Excitotoxicity-induced prostaglandin D production induces sustained microglial activation and delayed neuronal death.
J Lipid Res. 2017 Apr;58(4):649-655. doi: 10.1194/jlr.M070532. Epub 2017 Feb 7.
3
Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor.
PLoS One. 2013 Jun 10;8(6):e65767. doi: 10.1371/journal.pone.0065767. Print 2013.
4
Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand.
Br J Pharmacol. 2000 Nov;131(6):1025-38. doi: 10.1038/sj.bjp.0703686.
5
Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists.
Br J Pharmacol. 1999 May;127(1):204-10. doi: 10.1038/sj.bjp.0702490.
6
Modulation of noradrenaline release from the sympathetic nerves of the human saphenous vein and pulmonary artery by presynaptic EP3- and DP-receptors.
Br J Pharmacol. 1994 Mar;111(3):733-8. doi: 10.1111/j.1476-5381.1994.tb14799.x.
7
Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene.
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11192-6. doi: 10.1073/pnas.91.23.11192.
8
The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist.
Br J Pharmacol. 1989 Feb;96(2):291-300. doi: 10.1111/j.1476-5381.1989.tb11816.x.
9
Antagonism of PGD2 vasodepressor responses in the rat in vivo by the novel, selective antagonist, BW A868C.
Br J Pharmacol. 1989 Feb;96(2):307-12. doi: 10.1111/j.1476-5381.1989.tb11818.x.
10
Albumin-bound docosahexaenoic acid and collagen-induced human platelet reactivity.
Lipids. 1990 Mar;25(3):166-9. doi: 10.1007/BF02544332.
本文引用的文献
1
The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes.
Prostaglandins. 1984 Feb;27(2):321-33. doi: 10.1016/0090-6980(84)90083-2.
2
Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors.
Prostaglandins. 1983 Jan;25(1):13-28. doi: 10.1016/0090-6980(83)90131-4.
3
Studies on the characterisation of prostanoid receptors: a proposed classification.
Prostaglandins. 1982 Nov;24(5):667-89. doi: 10.1016/0090-6980(82)90036-3.
4
The use of a prostacyclin analogue, [3H]iloprost, for studying prostacyclin-binding sites on human platelets and neuronal hybrid cells.
Biosci Rep. 1984 Nov;4(11):941-8. doi: 10.1007/BF01116892.
5
A highly sensitive adenylate cyclase assay.
Anal Biochem. 1974 Apr;58(2):541-8. doi: 10.1016/0003-2697(74)90222-x.
6
The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist.
Br J Pharmacol. 1989 Feb;96(2):291-300. doi: 10.1111/j.1476-5381.1989.tb11816.x.
7
Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues.
Br J Pharmacol. 1986 Jan;87(1):97-107. doi: 10.1111/j.1476-5381.1986.tb10161.x.
8
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.
Nature. 1976 Oct 21;263(5579):663-5. doi: 10.1038/263663a0.
9
10
Selective binding site for [3H]prostacyclin on platelets.
J Clin Invest. 1979 Feb;63(2):215-20. doi: 10.1172/JCI109292.
Zotero 插件